PVLA
Income statement / Annual
Last year (2024), Palvella Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Palvella Therapeutics, Inc.'s net income was -$17.43 M.
See Palvella Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$8.15 M
|
$8.79 M
|
$13.88 M
|
| General & Administrative Expenses |
$5.94 M
|
$3.08 M
|
$4.16 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.94 M
|
$3.08 M
|
$4.16 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.10 M
|
$11.87 M
|
$18.04 M
|
| Cost And Expenses |
$14.10 M
|
$11.87 M
|
$18.04 M
|
| Interest Income |
$0.00
|
$6.27 M
|
$0.00
|
| Interest Expense |
$4.32 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$13.12 M |
$18.69 M |
-$18.04 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$3.34 M
|
$30.56 M
|
-$10.54 M
|
| Income Before Tax |
-$17.43 M
|
$18.69 M
|
-$28.58 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.03 M
|
| Net Income |
-$17.43 M
|
$18.69 M
|
-$27.55 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-7.83 |
1.6 |
-2.46 |
| EPS Diluted |
-7.83 |
1.6 |
-2.46 |
| Weighted Average Shares Out |
$2.23 M
|
$11.22 M
|
$11.22 M
|
| Weighted Average Shares Out Diluted |
$2.23 M
|
$11.22 M
|
$11.22 M
|
| Link |
|
|
|
